Principal Securities’s Innate Pharma IPHA Stock Holding History

Principal Securities’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-45	Closed	-$87	–	2433
2025 Q3	$87	Hold	45	–	–	﹤0.01%	3704
2025 Q2	$82	Buy	+45	New	+$91	﹤0.01%	3652

Other funds holding IPHA

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Principal Securities's IPHA Position: Q4 2025 in Review

Principal Securities sold out of Innate Pharma (IPHA) in Q4 2025, closing a stake of 45 shares — an estimated $87 sold.

Principal Securities first reported a position in IPHA in Q2 2025 and held it in 2 quarters. The position peaked at $87 in Q3 2025. 11 funds tracked by Wall St. Rank hold IPHA as of Q4 2025.

Principal Securities reported no remaining Innate Pharma position as of Q4 2025 after selling out during the quarter.
Principal Securities sold 45 Innate Pharma shares in Q4 2025, an estimated $87.
Principal Securities first reported a position in Innate Pharma in Q2 2025 and held it in 2 quarters.
Principal Securities's Innate Pharma position peaked at $87 in Q3 2025.
11 funds tracked by Wall St. Rank held Innate Pharma as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.